All In MedTech

Device Trial Radar · NCT00288418

Safety and Efficacy Study of Angiotech Central Venous Catheter to Prevent Bacterial Catheter Colonization

A Controlled, Randomized, Single-Blind, Multi-Center Pivotal Clinical Study Using Angiotech CVC to Prevent Bacterial Colonization on Short-Term Central Venous Catheters

Last checked: Nov 20, 2026Latest source record: Jan 23, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingTitle says "pivotal". Randomized with 960 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

960

Actual

Start

Dec 2005

Primary completion

Jul 2007

Study completion Jul 2007

Sponsor

Lead sponsor
Angiotech PharmaceuticalsNot on our public-company list
Sponsor type
Industry
First posted
Feb 8, 2006

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to determine if the Angiotech central venous catheter (CVC) is equal in effectiveness to a CVC coated with chlorhexidine and silver sulfadiazine in preventing bacterial catheter colonization. Other objectives of this study are to determine if the Angiotech CVC is equal in effectiveness to a CVC coated with chlorhexidine and silver sulfadiazine in preventing catheter-related local infection, and catheter-related bloodstream infection. This study will also assess the safety of the Angiotech CVC.

Conditions

  • Bacterial Infections

Interventions

  • Central Venous CatheterDevice

    7-French x 20-cm, triple lumen, short-term CVC vs. 7-French x 20-cm, triple lumen, short-term CVC with an anti-infective polymer coating, applied to the outer surface that contains the active pharmaceutical ingredient 5-fluorouracil (5-FU). The Angiotech CVC uses a 50µg/linear cm dose of 5-FU

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of catheter colonizationTime frame: Maximum of 28 days

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Cardio-Thoracic Surgeons, P.C.

    Birmingham, Alabama

  • Pulmonary Consultant Group

    Orange, California

  • Pulmonary Center Sharp Memorial Hospital

    San Diego, California

18 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.